Brant Barthle is a pharmacist who is specialized in Oncology in New York, New York. Patients can reach him at 525 E68th St, K306 - Starr 3 Pharmacy, New York or contact him on 212-746-3306. Active license number of Brant Barthle is PS42689 for Oncology in Florida. Brant Barthle is a licensed pharmacist who has demonstrated specialized knowledge and skill in developing, recommending, implementing, monitoring, and modifying pharmacotherapeutic plans to optimize outcomes in patients with malignant diseases.
Complete Profile:
Brant Barthle speciality, credentials, practice address, contact phone number and fax are as below. Patients can call on the below given phone number for enquiries.
Name:
Brant Barthle
Specialization:
Oncology
Gender:
Male
Location:
525 E68th St, K306 - Starr 3 Pharmacy, New York, New York, 10065
Phone:
212-746-3306
Professional Identification Codes:
NPI number stands for National Provider Identifier which is a unique 10-digit identification number issued to health care providers in the United States by the Centers for Medicare and Medicaid Services (CMS).
NPI details of Brant Barthle are as mentioned below.
NPI Number:
1699476192
NPI Enumeration Date:
13 Mar, 2023
NPI Last Update On:
13 Mar, 2023
Medical Licenses:
Pharmacists can have one or more medical licenses for different specialities in the same state or different states. Related medical licenses for Brant Barthle are as mentioned below.
Specialization
License Number
State
Status
Oncology
PS42689
Florida
Primary
Business Mailing Address:
Business mailing address can be used for mailing purpose only, for visiting purpose patients need to refer above mentioned address.
Address:
525 E68th St, K306 - Starr 3 Pharmacy New York, New York
Zip:
10065
Phone Number:
212-746-3306
Fax Number:
--
Patients can reach Brant Barthle at 525 E68th St, K306 - Starr 3 Pharmacy, New York, New York or can call on phone at 212-746-3306.
Comments/ Reviews:
*Data of this site is collected from Medicare & Medicaid Services (CMS) and NPPES. Last updated on 09 December, 2024.